miR-1226-5p is involved in radioresistance of colorectal cancer by activating M2 macrophages through suppressing IRF1.
Humans
Colorectal Neoplasms
/ genetics
MicroRNAs
/ genetics
Interferon Regulatory Factor-1
/ metabolism
Radiation Tolerance
/ genetics
Macrophages
/ metabolism
Cell Movement
/ genetics
Gene Expression Regulation, Neoplastic
Epithelial-Mesenchymal Transition
/ genetics
Animals
HCT116 Cells
Macrophage Activation
/ genetics
Carcinogenesis
/ genetics
Neoplasm Invasiveness
Base Sequence
Cell Line, Tumor
Organoids
/ metabolism
Mice
Mice, Nude
IRF1
M2 macrophage
Radioresistance of colorectal cancer
TGF-β
Tumor malignancy
circSLC43A1
miR-1226-5p
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
18
07
2024
accepted:
24
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Although the representative treatment for colorectal cancer (CRC) is radiotherapy, cancer cells survive due to inherent radioresistance or resistance acquired after radiation treatment, accelerating tumor malignancy and causing local recurrence and metastasis. However, the detailed mechanisms of malignancy induced after radiotherapy are not well understood. To develop more effective and improved radiotherapy and diagnostic methods, it is necessary to clearly identify the mechanisms of radioresistance and discover related biomarkers. To analyze the expression pattern of miRNAs in radioresistant CRC, sequence analysis was performed in radioresistant HCT116 cells using Gene Expression Omnibus, and then miR-1226-5p, which had the highest expression in resistant cells compared to parental cells, was selected. To confirm the effect of miR-1226-5 on tumorigenicity, Western blot, qRT-PCR, transwell migration, and invasion assays were performed to confirm the expression of EMT factors, cell mobility and invasiveness. Additionally, the tumorigenic ability of miR-1226-5p was confirmed in organoids derived from colorectal cancer patients. In CRC cells, IRF1, a target gene of miR-1226-5p, and circSLC43A1, which acts as a sponge for miR-1226-5p, were discovered and the mechanism was analyzed by confirming the tumorigenic phenotype. To analyze the effect of tumor-derived miR-1226-5p on macrophages, the expression of M2 marker in co-cultured cells and CRC patient tissues were confirmed by qRT-PCR and immunohistochemical (IHC) staining analyses. This study found that overexpressed miR-1226-5p in radioresistant CRC dramatically promoted epithelial-mesenchymal transition (EMT), migration, invasion, and tumor growth by suppressing the expression of its target gene, IRF1. Additionally, we discovered circSLC43A1, a factor that acts as a sponge for miR-1226-5p and suppresses its expression, and verified that EMT, migration, invasion, and tumor growth are suppressed by circSLC43A1 in radioresistant CRC cells. Resistant CRC cells-derived miR-1226-5p was transferred to macrophages and contributed to tumorigenicity by inducing M2 polarization and secretion of TGF-β. This study showed that the circSLC43A1/miR-1226-5p/IRF1 axis is involved in radioresistance and cancer aggressiveness in CRC. It was suggested that the discovered signaling factors could be used as potential biomarkers for diagnosis and treatment of radioresistant CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Although the representative treatment for colorectal cancer (CRC) is radiotherapy, cancer cells survive due to inherent radioresistance or resistance acquired after radiation treatment, accelerating tumor malignancy and causing local recurrence and metastasis. However, the detailed mechanisms of malignancy induced after radiotherapy are not well understood. To develop more effective and improved radiotherapy and diagnostic methods, it is necessary to clearly identify the mechanisms of radioresistance and discover related biomarkers.
METHODS
METHODS
To analyze the expression pattern of miRNAs in radioresistant CRC, sequence analysis was performed in radioresistant HCT116 cells using Gene Expression Omnibus, and then miR-1226-5p, which had the highest expression in resistant cells compared to parental cells, was selected. To confirm the effect of miR-1226-5 on tumorigenicity, Western blot, qRT-PCR, transwell migration, and invasion assays were performed to confirm the expression of EMT factors, cell mobility and invasiveness. Additionally, the tumorigenic ability of miR-1226-5p was confirmed in organoids derived from colorectal cancer patients. In CRC cells, IRF1, a target gene of miR-1226-5p, and circSLC43A1, which acts as a sponge for miR-1226-5p, were discovered and the mechanism was analyzed by confirming the tumorigenic phenotype. To analyze the effect of tumor-derived miR-1226-5p on macrophages, the expression of M2 marker in co-cultured cells and CRC patient tissues were confirmed by qRT-PCR and immunohistochemical (IHC) staining analyses.
RESULTS
RESULTS
This study found that overexpressed miR-1226-5p in radioresistant CRC dramatically promoted epithelial-mesenchymal transition (EMT), migration, invasion, and tumor growth by suppressing the expression of its target gene, IRF1. Additionally, we discovered circSLC43A1, a factor that acts as a sponge for miR-1226-5p and suppresses its expression, and verified that EMT, migration, invasion, and tumor growth are suppressed by circSLC43A1 in radioresistant CRC cells. Resistant CRC cells-derived miR-1226-5p was transferred to macrophages and contributed to tumorigenicity by inducing M2 polarization and secretion of TGF-β.
CONCLUSIONS
CONCLUSIONS
This study showed that the circSLC43A1/miR-1226-5p/IRF1 axis is involved in radioresistance and cancer aggressiveness in CRC. It was suggested that the discovered signaling factors could be used as potential biomarkers for diagnosis and treatment of radioresistant CRC.
Identifiants
pubmed: 39472937
doi: 10.1186/s12967-024-05797-1
pii: 10.1186/s12967-024-05797-1
doi:
Substances chimiques
MicroRNAs
0
Interferon Regulatory Factor-1
0
IRF1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
980Subventions
Organisme : Ministry of Science and ICT, South Korea
ID : NRF-2021R1A2C2005966(50698-2023)
Organisme : Ministry of Science and ICT, South Korea
ID : NRF-2017M2A2A7A01018542(50035-2019)
Organisme : Ministry of Science and ICT, South Korea
ID : 50531-2024
Informations de copyright
© 2024. The Author(s).
Références
Front Genet. 2019 Jul 18;10:626
pubmed: 31379918
Exp Mol Med. 2010 Apr 30;42(4):233-44
pubmed: 20177143
Am J Cancer Res. 2015 Jan 15;5(2):545-59
pubmed: 25973296
PLoS One. 2015 Aug 11;10(8):e0133870
pubmed: 26263387
Shock. 2016 Aug;46(2):122-31
pubmed: 26954942
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):584-591
pubmed: 28669750
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209703
Gastroenterology. 2016 Jun;150(7):1659-1672.e5
pubmed: 26946344
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
Cells. 2020 Jul 09;9(7):
pubmed: 32660072
Int J Mol Med. 2021 Jun;47(6):
pubmed: 33907823
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
World J Gastroenterol. 2022 Jul 14;28(26):3027-3046
pubmed: 36051330
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
Cancers (Basel). 2023 Feb 21;15(5):
pubmed: 36900159
J Transl Med. 2015 Aug 04;13:252
pubmed: 26238857
Int J Oncol. 2017 Oct;51(4):1239-1248
pubmed: 28849150
Nat Cell Biol. 2014 Sep;16(9):864-75
pubmed: 25086746
Biology (Basel). 2021 Jun 03;10(6):
pubmed: 34205090
Carcinogenesis. 2005 Sep;26(9):1527-35
pubmed: 15878912
PLoS Genet. 2013;9(9):e1003777
pubmed: 24039610
Adv Exp Med Biol. 2018;1087:67-79
pubmed: 30259358
Front Immunol. 2021 Sep 21;12:723609
pubmed: 34621270
Exp Mol Med. 2021 Jun;53(6):1029-1035
pubmed: 34135469
Front Mol Biosci. 2022 Feb 14;9:832916
pubmed: 35237661
Braz J Med Biol Res. 2021 Apr 02;54(5):e9700
pubmed: 33825780
J Exp Clin Cancer Res. 2023 Sep 19;42(1):242
pubmed: 37723588
Pharmacol Res. 2020 May;155:104745
pubmed: 32145401
Front Oncol. 2020 Jun 16;10:874
pubmed: 32612950
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
Genes (Basel). 2023 Jun 29;14(7):
pubmed: 37510280
Cancer Treat Rev. 2018 Apr;65:22-32
pubmed: 29502037
Cancer Cell Int. 2021 Jul 21;21(1):389
pubmed: 34289846
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Cancers (Basel). 2023 Mar 06;15(5):
pubmed: 36900416
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Cells. 2021 Nov 16;10(11):
pubmed: 34831416
Int J Mol Sci. 2024 May 31;25(11):
pubmed: 38892269
Epigenetics. 2015;10(6):545-61
pubmed: 25961636
Mol Ther. 2021 Jun 2;29(6):2088-2107
pubmed: 33571679
World J Gastrointest Surg. 2023 Apr 27;15(4):495-519
pubmed: 37206081
Cytokine. 2021 Dec;148:155709
pubmed: 34597918
World J Surg Oncol. 2022 Jul 27;20(1):241
pubmed: 35897096
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):497-505
pubmed: 19735874
Signal Transduct Target Ther. 2021 May 21;6(1):185
pubmed: 34016945
Front Immunol. 2019 Apr 17;10:799
pubmed: 31057539
Cell Death Differ. 2010 Apr;17(4):699-709
pubmed: 19851330
Exp Cell Res. 2023 Oct 1;431(1):113733
pubmed: 37517591
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406504
Mol Cancer. 2020 Mar 18;19(1):60
pubmed: 32188489
Front Immunol. 2014 Nov 28;5:614
pubmed: 25506346
Cancer Manag Res. 2019 Jul 04;11:6125-6138
pubmed: 31308749
Oncotarget. 2015 Jun 30;6(18):15984-94
pubmed: 25961730
Front Immunol. 2021 Jul 13;12:685978
pubmed: 34326840
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):298-313
pubmed: 32005946
Int J Clin Exp Pathol. 2021 Jan 01;14(1):9-23
pubmed: 33532019
Curr Opin Pharmacol. 2017 Aug;35:12-19
pubmed: 28538141
Genetics. 2024 Aug 7;227(4):
pubmed: 38963803
Oncol Rep. 2020 Aug;44(2):698-710
pubmed: 32627036
Biomed Pharmacother. 2021 Feb;134:111099
pubmed: 33338745
RNA Biol. 2019 Jul;16(7):899-905
pubmed: 31023147
Nat Rev Drug Discov. 2022 Nov;21(11):799-820
pubmed: 35974096
Int J Mol Sci. 2024 Mar 19;25(6):
pubmed: 38542436
PLoS Comput Biol. 2019 Nov 18;15(11):e1007468
pubmed: 31738746
Cancer Lett. 2015 Dec 28;369(2):289-97
pubmed: 26427840
FEBS Open Bio. 2021 May;11(5):1343-1352
pubmed: 33665967